Antibodies are widely used in life science research, assay development, and bioprocess workflows because of their specificity, affinity, and format flexibility. Different targets, epitopes, species strategies, and downstream applications often require different discovery routes and development workflows. A practical antibody platform therefore needs both technical diversity and a connected project pathway.

Nebulabio Antibody Discovery Platform provides a unified service framework covering discovery technologies, library construction and screening, premade and immunized library resources, custom antibody development, recombinant and high-throughput production, purification and labeling, and supporting cell line engineering. The platform is designed to support flexible program execution with clear deliverables, consistent process logic, and application-ready outputs.

Nebulabio integrated antibody discovery platform incorporates diverse technology modalities to support customized strategies tailored to each program’s scientific and translational objectives. These discovery technologies can be used independently or combined within one program.

• Phage Display Platform for in vitro antibody screening workflows using recombinant proteins, cells, or target-expressing systems.

• Antibody Phage Display Platform for target-specific binder enrichment, specificity-focused selection, and downstream screening support across diverse antigen types.

• scFv Phage Display Platform for single-chain variable fragment discovery and screening workflows compatible with downstream reformatting and engineering.

• VHH Phage Display Platform for single-domain antibody discovery programs requiring compact binders and flexible screening design.

• Fab Phage Display Platform for Fab-format screening workflows in fragment-based discovery and reformatting-oriented projects.

• Single B Cell Sorting Platform for direct isolation of antigen-specific B cells and recovery of native heavy/light chain pairs from immunized sources or selected donors.

• Hybridoma Platform for monoclonal antibody generation using immunization, cell fusion, clone screening, and clone development workflows.

This technology group provides the foundation for program-specific discovery design, with options matched to target characteristics and project requirements.

Phage Display Library quality and screening strategy are core factors in antibody diversity and binder recovery. Our library service module covers both custom library generation and screening workflows across multiple display formats.

• Phage Display Library Construction for custom library design and generation aligned with target-specific discovery programs.

• scFv Library Construction Service for building scFv libraries optimized for screening throughput and downstream engineering flexibility.

• Fab Library Construction Service for Fab-format library generation in fragment-based antibody discovery workflows.

• VHH Library Construction Service for single-domain antibody library generation tailored to nanobody-oriented programs.

• Phage Display Library Screening for binder enrichment, hit identification, and early-stage lead selection from display libraries.

• scFv Library Screening Service for scFv-specific screening workflows with customizable panning and enrichment conditions.

• Fab Library Screening Service for Fab binder discovery with project-matched screening strategies.

• VHH Library Screening Service for VHH/single-domain screening workflows focused on efficient lead generation.

These services include library preparation support, diversity evaluation, QC steps, and target-specific screening workflow design to support reliable downstream results.

To support faster project initiation, our platform includes premade and immunized library resources that can be used directly in screening workflows. This module is suitable for feasibility studies, rapid hit generation, and time-sensitive discovery programs.

• Premade Phage scFv Library for direct screening of scFv binders in early-stage or accelerated discovery workflows.

• Premade Phage VHH Library for direct screening of single-domain antibody binders, including programs focused on compact formats and conformational epitopes.

• Mouse Immunized Antibody Library for discovery programs using immunized repertoires with in vivo-matured antigen responses.

• Alpaca Immunized Antibody Library for camelid-derived VHH discovery workflows using immunized alpaca repertoires.

• Light Chain Antibody Library for specialized screening and engineering workflows requiring light-chain-focused diversity.

• Premade Antibody Library Screening for direct binder screening using existing antibody libraries with project-specific enrichment strategies.

• Premade Single Domain Antibody Library Screening for VHH/single-domain screening using premade library resources and target-focused panning workflows.

• Premade Peptide Library Screening for peptide binder identification and interaction-oriented screening programs.

This resource module helps reduce startup time while maintaining flexibility in screening strategy and output format.

Our integrated platform supports multiple discovery modalities beyond a single workflow type. This service group is designed to align discovery strategy with target biology, species preference, and output format requirements.

• Single B Cell Sorting Platform Services for direct isolation of antigen-specific B cells and native antibody pair recovery in programs prioritizing natural pairing and rapid progression.

• Monoclonal Antibody Discovery for high-specificity antibody generation and downstream screening support.

• Polyclonal Antibody Discovery for broad epitope-recognition workflows and antigen-response programs.

• Peptide Discovery for peptide binder identification and interaction-focused screening applications.

• Native Antibody Discovery Services for programs requiring antibodies derived from natural immune repertoires.

These services can be combined with Hybridoma, Phage Display, or Single B Cell Sorting workflows to build a project-specific discovery route.

We deliver integrated custom antibody development solutions across a broad range of host species, including mouse, rabbit, hamster, canine, feline, bovine, chicken (IgY), duck, and camelids such as llama and alpaca for VHH/single-domain antibody generation. Species selection is strategically aligned with target immunogenicity, epitope diversity, downstream application, and translational objectives. Our programs support discovery, assay development, diagnostics, veterinary research, and preclinical studies.

• Monoclonal Antibody Production 

Our monoclonal antibody services provide fully customized development workflows, from antigen strategy and immunization through hybridoma or recombinant platform generation, clone screening, subcloning, sequencing, recombinant expression, and scalable production. Each program is designed to achieve defined specificity, affinity, isotype, and functional performance criteria, with flexible purification and formulation options to match research or application needs.

• Polyclonal Antibody Production 

We offer tailored polyclonal antibody production programs optimized for antigen characteristics and intended applications. Services include immunization protocol design, serum collection, affinity purification, titer evaluation, and optional conjugation or bulk production. Quality control parameters and purification strategies are defined according to project-specific requirements to ensure consistency and reproducibility.

• Nanobody (VHH) Production

For applications requiring small size, high stability, and unique epitope accessibility, we provide custom nanobody development based on camelid immune repertoires. Our VHH services encompass immunization, library construction, screening and affinity maturation, sequence validation, recombinant expression, and scalable production. Nanobodies can be delivered in standalone formats or engineered into fusion constructs to support advanced research and therapeutic exploration.

Across all antibody formats, we combine species diversity, platform flexibility, and production scalability to accelerate your program from concept to validated reagent.

Our downstream antibody module supports production and processing workflows that convert validated candidates into consistent, application-ready materials. Services can be used as standalone modules or as part of integrated discovery-to-delivery programs.

• Recombinant Antibody Productionfor sequence-confirmed recombinant antibody expression and purified material preparation.

• Recombinant Antibody Production Services for project-specific recombinant workflows covering expression optimization and material delivery.

• High-throughput Antibody Production for parallel expression and processing of multiple antibody candidates in screening programs.

• High-throughput Antibody Production Service for standardized batch workflows supporting clone comparison and ranking.

• Antibody Purification for antibody purification workflows with polishing, buffer exchange, and QC-ready output options.

• Antibody Purification Services for standalone or integrated purification support across recombinant and conventionally produced antibodies.

• Antibody Conjugation and Labeling Services for fluorophore, biotin, enzyme, and other tag-based conjugation workflows.

• Custom Antibody Labeling for project-specific labeling formats and downstream assay compatibility.

This service group supports assay development and research workflows by providing consistent antibody materials in ready-to-use formats.

Cell-based systems are often required for immunization support, screening workflows, and functional characterization. Our cell line module complements antibody discovery by providing engineered cell models aligned with antibody project needs.

• Stable Cell Line Development Platform for integrated target-expressing and assay-supporting cell line workflows.

• High-performance CHO Stable Cell Line Development for CHO-based stable cell model generation and long-term project support.

• High-performance HEK293 Stable Cell Line Development for HEK293-based stable line development in expression and assay programs.

• Biosimilar Cell Line Development for cell line engineering workflows supporting comparability-focused or format-matched development programs.

These services help maintain process continuity between target biology, screening systems, and downstream antibody evaluation workflows.

Why Choose Nebulabio Antibody Discovery Platform

Nebulabio Antibody Discovery Platform is structured to provide technical coverage, process continuity, and flexible execution across discovery and development programs.

• Integrated workflow: Discovery, library services, production, purification, labeling, and cell line development can be organized within one project framework.

• Technology diversity: Hybridoma, Phage Display, and Single B Cell Sorting support multiple discovery routes and target types.

• Flexible resources: Custom libraries, premade libraries, and immunized libraries support both rapid-start and tailored discovery programs.

• Broad development coverage: The platform supports monoclonal, polyclonal, recombinant, species-derived, and VHH antibody workflows.

• Application-ready outputs: Purification, conjugation, labeling, and cell line support help streamline transition into assay and research workflows.